• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
OB
CMECNE

The Spectrum of Fetal Arrhythmias – From a Common Finding to a Serious Concern

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Categorize different fetal arrhythmias based on regularity and rate
2. Recall features of premature atrial contractions (PACs)

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Jan 25 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

WHAT IS IT?

A fetal arrhythmia is an abnormality in fetal heart rate and/or cardiac rhythm. Most often, the unusual rhythm is detected during an otherwise normal prenatal visit.

Arrhythmias presenting with an irregular rhythm include:

  • Premature Atrial Contractions (PACs)
    • PACs are common in fetuses and may be seen in up to 51% of healthy newborns
      • A premature atrial contraction is usually followed by a ventricular contraction that will also be premature, but will occur at the appropriate time in the cycle
      • There is a low risk of fetal tachycardia
      • Considered normal at birth unless other problems are found in the nursery
    • PACs will usually spontaneously resolve
  • Premature Ventricular Contractions (PVCs)
    • Fetal PVCs are considerably less common than PACs
    • The PVC is not preceded by a normal atrial beat
    • In isolation, PVCs should be monitored regularly, but intervention is usually not required

Arrhythmias presenting with a slow heart rate include:

  • Sinus Bradycardia – 80-110 bpm (beats per minute)
    • The rhythm appears normal but the rate is slow with respect to gestational age
    • May be well tolerated and require monitoring but no intervention
    • Underlying causes can include non-reassuring fetal status or cardiac structural defects, or maternal antibodies such as anti-SSA (Ro), which may require anti-inflammatory therapy
  • Complete Heart Block (CHB) – 40-80 bpm
    • This is a complete failure of normal atrial impulses to the ventricles such that the atria and ventricles are no longer coordinated
    • Underlying causes can include cardiac structural defects (50%)
    • Maternal anti-SSA (Ro) anti-SSB (La) autoantibodies are  strongly associated with CHB and there is an associated risk of fetal loss, especially with fetal heart rate below 55 bpm
      • Mothers are often asymptomatic with no evidence of autoimmune disease such as lupus
        • antibodies first detected upon evaluation for fetal arrhythmia
      • The risk for acquired heart block in the fetus in the setting of maternal anti-SSA and anti-SSB antibodies is approximately 2–3%, with a recurrence risk of 14–17%
      • In newborn with otherwise normal cardiac exam but CHB, likely cause is autoantibodies
      • Cutaneous findings consistent with neonatal lupus erythematosus are more common (16%), than CHB with anti-SSA/SSB
    • Medical therapy may be used prenatally in the case of antibody related CHB with pacing after delivery

Arrhythmias presenting with an increased heart rate include: 

  • Fetal heart rate above 180 bp should be considered critical
    • Supraventricular Tachycardia (SVT) – 190-300 bpm
      • May be monitored if infrequent but otherwise maternal anti-arrhythmic therapy (e.g. digoxin) may be required
    • Atrial Flutter (FT) – ventricular rate – 150-250 bpm
      • Almost exclusively seen in the 3rd trimester or at birth
      • Usually well tolerated and can be treated with maternal anti-arrhythmic agents (e.g. digoxin)
    • Sinus Tachycardia – 200+ bpm
      • Look for and manage underlying cause such as infection or non-reassuring fetal status

KEY POINTS:

  • Identifying an unusual fetal cardiac rhythm or rate during a normal antepartum visit may be a key moment in detecting a significant cardiac arrhythmia
  • Even though fetuses may easily tolerate irregular rhythms such as PACs, any change from a normal heart rate or regular rhythm pattern should trigger a referral to a high risk specialist who can make the diagnosis and with a multidisciplinary team, can determine whether to monitor, treat or deliver
  • Fetal echocardiography remains the mainstay of diagnosis, as well as a detailed fetal anatomy scan to determine if any other structural abnormalities exist
    • Refer to high risk center for diagnosis and management plan
  • The above list constitutes the more common types of fetal arrhythmias, but more complex and rare forms may exist

Learn More – Primary Sources:

Fetal arrhythmias: diagnosis and treatment

Fetal and Neonatal Arrhythmias

Diagnosis and treatment of fetal arrhythmia

Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options

Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies

Locate a Maternal Fetal Medicine Specialist

Maternal Fetal Medicine Specialist Locator-SMFM

Take a post-test and get CME credits

TAKE THE POST TEST

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More  »

image_pdfFavoriteLoadingFavorite

< Previous
All OB Posts
Next >

Related ObG Topics:

Is the Use of Beta-blockers in Pregnancy Related to Fetal Cardiac Anomalies?
Practical obstetrics info for your women's healthcare practice
Echogenic Intracardiac Focus – What is the Clinical Significance?
Practical obstetrics info for your women's healthcare practice
Single Umbilical Artery, or the “Two Vessel Cord”: What Does it Mean? 
Practical obstetrics info for your women's healthcare practice

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site